InflaRx N.V. (NASDAQ:IFRX) Receives Average Recommendation of “Moderate Buy” from Analysts

InflaRx N.V. (NASDAQ:IFRX) has been assigned an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $7.00.

A number of research firms have weighed in on IFRX. Guggenheim restated a “buy” rating and set a $14.00 target price on shares of InflaRx in a report on Tuesday, April 21st. Weiss Ratings restated a “sell (d-)” rating on shares of InflaRx in a report on Friday, March 27th. HC Wainwright upped their target price on InflaRx from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Monday. Raymond James Financial upgraded InflaRx from an “outperform” rating to a “strong-buy” rating and upped their target price for the stock from $7.00 to $9.00 in a report on Wednesday. Finally, Oppenheimer started coverage on InflaRx in a report on Friday, April 24th. They set an “outperform” rating and a $5.00 target price for the company.

Hedge Funds Weigh In On InflaRx

Large investors have recently made changes to their positions in the business. Woodline Partners LP acquired a new position in shares of InflaRx during the first quarter worth $766,000. Squarepoint Ops LLC increased its position in shares of InflaRx by 72.0% during the fourth quarter. Squarepoint Ops LLC now owns 324,349 shares of the company’s stock worth $328,000 after purchasing an additional 135,826 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in shares of InflaRx in the 2nd quarter valued at $262,000. Boothbay Fund Management LLC increased its position in shares of InflaRx by 10.8% in the 3rd quarter. Boothbay Fund Management LLC now owns 175,114 shares of the company’s stock valued at $235,000 after acquiring an additional 17,056 shares during the period. Finally, ADAR1 Capital Management LLC acquired a new position in shares of InflaRx in the 3rd quarter valued at $214,000. 42.39% of the stock is owned by institutional investors and hedge funds.

InflaRx Stock Up 3.8%

InflaRx stock opened at $2.47 on Friday. The business has a fifty day moving average of $1.38 and a two-hundred day moving average of $1.18. The firm has a market cap of $178.56 million, a P/E ratio of -3.48 and a beta of 2.42. InflaRx has a twelve month low of $0.71 and a twelve month high of $2.95.

InflaRx (NASDAQ:IFRX) last posted its earnings results on Thursday, May 7th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.08. Equities analysts expect that InflaRx will post -0.51 earnings per share for the current year.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.